| 表格4 |
美國證券交易所(SEC) 華盛頓特區20549 有關受益所有權的變動聲明 根據1934年證券交易法第16(a)條或1940年投資公司法第30(h)條申報 或1940年投資公司法第30（h）條款 |
|
|||||||||||||||
| 請參見指令1(b)。請參閱 1. 報告人的姓名和地址 | |||||||||||||||||
| 勾選該框表示交易是根據購買或銷售發行方權益證券的合同，指示或書面計劃進行的，旨在滿足10b5-1(c)規則的肯定防禦條件。參見指令10。 | |||||||||||||||||
1. 報告人姓名和地址*
(街道)
|
2. 發行人名稱 和 逐筆明細或交易標的
Janux Therapeutics，公司。 [ JANX ] |
5. 報告人與發行人之間的關係
(勾選所有適用項)
|
||||||||||||||||||||||||
|
3. 最早交易日期
(月/日/年) 09/26/2024 | ||||||||||||||||||||||||||
|
4. 如有修正，最初提交日期
(月/日/年) |
6. 個人或聯合/團體申報（選擇適用的行）
|
| 表格I-已獲取、已處置或有利益佔有的非衍生證券 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. 證券名稱（說明書第3條） | 2. 交易日期（月/日/年） | 2A. 如有，則被視爲執行日期（月/日/年） | 3. 交易代碼（說明書第8條） | 4. 已獲取的證券（A）或已處置的證券（D）（說明書第3、4和5條） | 5. 報告交易後擁有的證券數量（說明書第3和4條） | 6. 擁有形式：直接（D）或間接（I）（說明書第4條） | 7. 間接利益所有權的性質（說明書第4條） | |||
| 代碼 | V | 數量 | （A）或（D） | 價格 | ||||||
| 普通股 | 09/26/2024 | S | 49,497 | D | $46.78(1) | 2,909,678 | D(2) | |||
| 普通股 | 09/26/2024 | S | 9,592 | D | $46.78(1) | 563,635 | I | 由安防-半導體生物風投I號有限合夥(3) | ||
| 普通股 | 09/26/2024 | S | 50,539 | D | $46.78(1) | 2,970,875 | I | 由Avalon BioVentures SPV I，L.P.提供(4) | ||
| 普通股 | 09/26/2024 | S | 40,803 | D | $47.77(5) | 2,868,875 | D(2) | |||
| 普通股 | 09/26/2024 | S | 7,908 | D | $47.77(5) | 555,727 | I | 由Avalon BioVentures I，LP提供(3) | ||
| 普通股 | 09/26/2024 | S | 41,661 | D | $47.77(5) | 2,929,214 | I | 由Avalon BioVentures SPV I，LP提供(4) | ||
| 普通股 | 09/27/2024 | S | 45,894 | D | $46.42(6) | 2,822,981 | D(2) | |||
| 普通股 | 09/27/2024 | S | 8,894 | D | $46.42(6) | 546,833 | I | 通過Avalon BioVentures I，LP(3) | ||
| 普通股 | 09/27/2024 | S | 46,861 | D | $46.42(6) | 2,882,353 | I | 通過Avalon BioVentures SPV I，L.P.(4) | ||
| 普通股 | 09/27/2024 | S | 1,511 | D | $47.74(7) | 2,821,470 | D(2) | |||
| 普通股 | 09/27/2024 | S | 293 | D | $47.74(7) | 546,540 | I | 通過Avalon BioVentures I，LP(3) | ||
| 普通股 | 09/27/2024 | S | 1,542 | D | $47.74(7) | 2,880,811 | I | 由Avalon BioVentures SPV I，L.P.提供(4) | ||
| 普通股 | 09/27/2024 | M | 828 | A | $17 | 7,828 | D(8) | |||
| 普通股 | 09/27/2024 | M | 345 | A | $10.73 | 8,173 | D(8) | |||
| 普通股 | 09/27/2024 | M | 345 | A | $13.22 | 8,518 | D(8) | |||
| 普通股 | 09/27/2024 | M | 234 | A | $39.8 | 8,752 | D(8) | |||
| 普通股 | 09/27/2024 | S | 1,826 | D | $46.19(9) | 6,926 | D(8) | |||
| 普通股 | 09/30/2024 | M | 434 | A | $17 | 7,360 | D(8) | |||
| 普通股 | 09/30/2024 | M | 181 | A | $10.73 | 7,541 | D(8) | |||
| 普通股 | 09/30/2024 | M | 181 | A | $13.22 | 7,722 | D(8) | |||
| 普通股 | 09/30/2024 | M | 123 | A | $39.8 | 7,845 | D(8) | |||
| 普通股 | 09/30/2024 | S | 958 | D | $46.24(10) | 6,887 | D(8) | |||
|
表 II-收購、處置或實益擁有的衍生證券 （例如，看跌期權、看漲期權、認股權證、期權、可轉換證券） | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1。衍生證券的標題（Instr. 3) | 2。衍生證券的兌換價或行使價 | 3。交易日期 （月/日/年） | 3A。視爲執行日期（如果有） （月/日/年） | 4。交易代碼（Instr. 8) | 5。 收購（A）或處置的衍生證券數量（D）（Instr. 3、4 和 5) | 6。可行使日期和到期日 （月/日/年） | 7。衍生證券標的證券所有權和金額（Instr. 3 和 4) | 8。衍生證券價格（Instr. 5) | 9。 報告交易後實益擁有的衍生證券數量（Instr. 4) | 10。所有權形式：直接（D）或間接（I）（Instr. 4) | 11。間接受益所有權的性質（Instr. 4) | ||||
| 代碼 | V | (A) | (D) | 可行使日期 | 到期日期 | 標題 | 股份金額或數量 | ||||||||
| 股票期權（買入權） | $17 | 09/27/2024 | M | 828 | (11) | 07/19/2027 | 普通股 | 828 | $0 | 28,178 | D(8) | ||||
| 股票期權（買入權） | $10.73 | 09/27/2024 | M | 345 | (11) | 07/19/2027 | 普通股 | 345 | $0 | 11,741 | D(8) | ||||
| 股票期權（買入權） | $13.22 | 09/27/2024 | M | 345 | (11) | 07/19/2027 | 普通股 | 345 | $0 | 11,741 | D(8) | ||||
| 股票期權（買入權） | $39.8 | 09/27/2024 | M | 234 | (11) | 07/19/2027 | 普通股 | 234 | $0 | 7,839 | D(8) | ||||
| 股票期權（買入權） | $17 | 09/30/2024 | M | 434 | (11) | 07/19/2027 | 普通股 | 434 | $0 | 27,744 | D(8) | ||||
| 股票期權（買入權） | $10.73 | 09/30/2024 | M | 181 | (11) | 07/19/2027 | 普通股 | 181 | $0 | 11,560 | D(8) | ||||
| 股票期權（買入權） | $13.22 | 09/30/2024 | M | 181 | (11) | 07/19/2027 | 普通股 | 181 | $0 | 11,560 | D(8) | ||||
| 股票期權（買入權） | $39.8 | 09/30/2024 | M | 123 | (11) | 07/19/2027 | 普通股 | 123 | $0 | 7,716 | D(8) | ||||
1. 報告人姓名和地址*
(街道)
呈報人與發行人的關係
| ||||||||||||||||||||||||
1. 報告人姓名和地址*
(街道)
呈報人與發行人的關係
| ||||||||||||||||||||||||
1. 報告人姓名和地址*
(街道)
呈報人與發行人的關係
| ||||||||||||||||||||||||
1. 報告人姓名和地址*
(街道)
呈報人與發行人的關係
|
| Explanation of Responses: |
| 1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 2. The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 3. The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 4. The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| 5. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 8. The securities are directly held by Mr. Lichter. |
| 9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.11 to $46.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.24 to $46.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 11. Immediately exercisable. |
| Avalon Ventures XI, L.P., By: Avalon Ventures XI GP, LLC, its general partner, By /s/ Jay B. Lichter, Authorized Signatory | 09/30/2024 | |
| Avalon BioVentures I, LP, By: Avalon BioVentures GP, LLC, its general partner, By /s/ Jay B. Lichter, Authorized Signatory | 09/30/2024 | |
| Avalon BioVentures SPV I, LP, By: ABV SPV I GP, LLC, its general partner, By /s/ Jay B. Lichter, Authorized Signatory | 09/30/2024 | |
| /s/ Jay B. Lichter | 09/30/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||